stars 1 stars 2 stars 3

Our patented novel Ensilication technology uses silica to create an individually tailored protective nanoshell around vaccines, antibodies and enzymes to prevent degradation, which can lead to spoilage. Once applied, the material can be stored and transported without the need for cold chain infrastructure, improving global access to medicines and reducing wastage and emissions across the pharmaceutical supply chain. Ensilication preserves the integrity of a wide variety of biomolecules and proteins, not only protecting against environmental degradation, but also making possible the development of more convenient administration such as subcutaneous and oral delivery for both humans and animals. We are actively looking for partners to work with us in developing ensilicated products, free from cold chain dependence. Please don’t hesitate to contact us if you’re interested in finding out more about us, and how our technology may benefit your products.

EnsiliTech Questions

Asel Sartbaeva is the Co-founder and CEO of EnsiliTech.

14 people are employed at EnsiliTech.

EnsiliTech is based in Bristol, England.

Top EnsiliTech Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users